Preventing orthopedic implant infection with disruptive UB technology

Garwood Medical Devices' approach to infection control is through a minimally invasive medical device that uses a low-voltage electrical current with a goal to kill antibiotic-resistant bacteria on metal implants. Patented by the University at Buffalo and Syracuse University and exclusively licensed by Garwood Medical, the technology behind the device served as the catalyst for a multifaceted, collaborative partnership between the life sciences company and the university.


How Garwood Medical collaborates with UB


Accelerates R&D


Licenses Technology


Recruits Talent


Collaborates with Experts


Occupies Lab Space


Uses High-tech Equipment

High Performance Computing.

High Performance Computing


Accesses Funding

Operates Tax-Free.

Operates Tax Free


Devastating impacts of implant infection

Each year in the United States, hundreds of thousands of people suffer from orthopedic implant infections that are extremely difficult to cure. In some cases, antibiotic-resistant bacteria form a slime or “biofilm” on an implant. The film acts as a barrier that shields the harmful bacteria from antibiotics or the patient’s immune system.

Current treatment options are painful and invasive, typically involving surgery to remove the infected implant. This costs patients and the healthcare system tens of billions of dollars per year and often still results in joint fusions, amputations and deaths. Treatment innovations could cure these serious infections and preserve implants, saving limbs and lives.

Garwood challenge.
Garwood Solution.


Innovation could lead to better infection control

Technology licensed from UB and Syracuse University is the driving force behind Garwood Medical’s BioPrax™— a minimally invasive medical device that aims to prevent and treat orthopedic implant infections without the need for implant removal. When doctors detect a biofilm infection, BioPrax™ uses a needle to deliver a low-voltage electrical stimulation to the metal implant, which has been shown in extensive pre-clinical testing to break up biofilms, kill bacteria and will target infection prevention in the future.

BioPrax™ is expected to reduce patient morbidity and mortality, prevent unnecessary surgeries, retain implants, help maintain biomechanical stability and mobility and save billions of dollars per year worldwide.


Accelerating commercialization

Beyond licensing multiple technologies from UB, Garwood Medical leverages UB’s supercomputing facility and expertise to perform high-fidelity simulations to analyze heat transfer, electrochemistry and blood flow data. These types of collaborative R&D projects inform current and future design improvements and optimization.

With multiple research projects jointly funded by UB, the company has moved BioPrax™ from proof of concept in a petri dish to large animal surgical safety and efficacy testing in a Good Laboratory Practice (GLP) preclinical research center at UB.

Garwood Medical’s partnership with UB helped them gain FDA Breakthrough Device status and win millions of dollars in funding. In turn, this allowed them to recruit expert biomedical engineering graduates from UB to support R&D efforts, expansion and revenue growth.


When businesses and universities join forces, great impacts result

Resources for discovery and growth

Solve a technical problem, grow your business, or launch a new venture with cutting-edge technologies from UB.

Make immediate business impact by attracting top talent from our pool of more than 30,000 smart, diverse and driven students.


Grow your business with the help of experts, cutting-edge facilities and equipment, advanced genomic and proteomic capabilities and funding through our Center of Excellence in Bioinformatics and Life Sciences.